Cargando…
Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology
Inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn’s disease, are chronic pathologies associated with a deregulated immune response in the intestinal mucosa, and they are triggered by environmental factors in genetically susceptible individuals. Exogenous glucocorticoids (GCs)...
Autores principales: | Dubois-Camacho, Karen, Ottum, Payton A, Franco-Muñoz, Daniel, De la Fuente, Marjorie, Torres-Riquelme, Alejandro, Díaz-Jiménez, David, Olivares-Morales, Mauricio, Astudillo, Gonzalo, Quera, Rodrigo, Hermoso, Marcela A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643284/ https://www.ncbi.nlm.nih.gov/pubmed/29085208 http://dx.doi.org/10.3748/wjg.v23.i36.6628 |
Ejemplares similares
-
Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget
por: Núñez F, Paulina, et al.
Publicado: (2022) -
Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis
por: Núñez F, Paulina, et al.
Publicado: (2021) -
Glucocorticoids Impair Phagocytosis and Inflammatory Response Against Crohn’s Disease-Associated Adherent-Invasive Escherichia coli
por: Olivares-Morales, Mauricio Javier, et al.
Publicado: (2018) -
Landscapes and bacterial signatures of mucosa-associated intestinal microbiota in Chilean and Spanish patients with inflammatory bowel disease
por: Chamorro, Nayaret, et al.
Publicado: (2021) -
Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
por: Jarmakiewicz-Czaja, Sara, et al.
Publicado: (2022)